Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $41.00 Average Target Price from Analysts

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has been given an average recommendation of “Moderate Buy” by the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $41.00.

Several equities research analysts have commented on ELVN shares. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, October 8th.

Insider Activity

In other Enliven Therapeutics news, COO Anish Patel sold 6,663 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $21.02, for a total value of $140,056.26. Following the sale, the chief operating officer directly owned 263,311 shares of the company’s stock, valued at approximately $5,534,797.22. This trade represents a 2.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Joseph P. Lyssikatos sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $16.84, for a total value of $84,200.00. Following the transaction, the insider directly owned 897,688 shares of the company’s stock, valued at approximately $15,117,065.92. The trade was a 0.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 68,330 shares of company stock worth $1,434,762 in the last ninety days. Company insiders own 25.90% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ELVN. Invesco Ltd. lifted its holdings in Enliven Therapeutics by 4.3% during the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock valued at $440,000 after purchasing an additional 913 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the last quarter. Quantbot Technologies LP raised its position in shares of Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the last quarter. Legal & General Group Plc lifted its stake in Enliven Therapeutics by 4.8% in the 3rd quarter. Legal & General Group Plc now owns 33,765 shares of the company’s stock valued at $691,000 after buying an additional 1,540 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Enliven Therapeutics by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after buying an additional 1,693 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

NASDAQ:ELVN opened at $15.14 on Friday. The firm’s fifty day moving average is $19.18 and its two-hundred day moving average is $19.94. The firm has a market cap of $898.56 million, a price-to-earnings ratio of -8.23 and a beta of 0.41. Enliven Therapeutics has a one year low of $13.30 and a one year high of $24.64.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.11. As a group, equities research analysts predict that Enliven Therapeutics will post -1.95 earnings per share for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.